



Contact:

Michael Kamdar
VentiRx Pharmaceuticals, Inc.
(858) 436-8525
mkamdar@ventirx.com

VentiRx Pharmaceuticals Appoints Kent Snyder to Board of Directors

San Diego, CA – April 16, 2007 – VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, announced today the appointment of Kent Snyder to its Board of Directors.

“We are pleased to have Kent join our Board of Directors,” said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. “Kent brings to VentiRx a long history of success and business leadership. His insights will be very valuable as we continue to build our business and prepare to enter the clinic with our first product candidate.”

Mr. Snyder has served as President and Chief Executive Officer and member of the Board of Directors of Senomyx, Inc. (Nasdaq: SNMX), a San Diego-based biotechnology company, since 2003. He is also on the Board of Directors of Santarus, Inc. (Nasdaq: SNTS). Previously he spent 10 years with Agouron Pharmaceuticals, Inc., now a Pfizer company, in a variety of senior marketing and business development positions, including President of Global Commercial Operations, Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder received a B.S. from the University of Kansas and an M.B.A. from Rockhurst College.

“I am pleased to be joining the Board of VentiRx,” said Mr. Snyder. “VentiRx is a rapidly emerging company equipped with a talented management team, a seasoned Board and ample financing. I look forward to working with management and the other members of the Board to build a successful company.”

“We welcome Kent to the Board,” said Patrick Heron, General Partner at Frazier Healthcare Ventures and a member of the Company’s Board of Directors. “Kent’s background is an ideal complement to our current Board’s experience as we continue to build VentiRx. We look forward to working with Kent.”

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, infectious, respiratory and autoimmune diseases. Founded in June 2006, VentiRx has assembled a team of biotechnology professionals with decades of business development and drug development experience in various therapeutic areas, with a particular expertise in innate immunity. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in San Diego with operations in Seattle. For additional information, please visit www.ventirx.com.

###